Drug intelligence / Profile preview

9-Butyl-8-(3-methoxybenzyl)-9H-purin-6-amine

Development stage: Unknown
Modality: Small Molecules

Overview

9-Butyl-8-(3-methoxybenzyl)-9H-purin-6-amine is an experimental small molecule belonging to the class of 6-aminopurines. It acts as an inhibitor of heat shock protein HSP 90-alpha (HSP90AA1), a molecular chaperone involved in the folding and stabilization of various client proteins critical for cell survival and proliferation. By inhibiting HSP90-alpha, this compound may disrupt multiple signaling pathways relevant to cancer and other diseases characterized by aberrant protein homeostasis. The compound has not been approved for clinical use or advanced beyond preclinical/experimental stages[1][2][10].

Other names: 9-Butyl-8-(3-Methoxybenzyl)-9h-Purin-6-AminePU5PU-5PU 5

Targets

HSP90AA1 (Heat shock protein HSP90-alpha)

Beyond the preview

Go deeper on 9-Butyl-8-(3-methoxybenzyl)-9H-purin-6-amine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 9-Butyl-8-(3-methoxybenzyl)-9H-purin-6-amine.

Explore the full profile